Showing posts with label schizophrenia. Show all posts
Showing posts with label schizophrenia. Show all posts

Wednesday, November 5, 2014

How Marijuana Effects GABA in the Nervous System


In short, GABA is a neurotransmitter in the mammal central nervous system that can repress excitability in the neurons in the nervous system and regulation in muscle tone. GABA is an abbreviation for gamma-Aminobutyric Acid which is an amino acid, which are secondary to water to being the biggest component in cells, tissue and muscle that are critical to biosynthesis and being a neurotransmitter. Cannabis plays a crucial role with the endocannabinoid system in suppressing the GABA, aiding in increasing dopamine levels which can help in treatments with medical marijuana.



GABA acts differently in stages of life, playing a roll in the developing brain as an excitatory component in the brain, while in adulthood acting as an inhibition in the brain. GABA regulates embryonic and neural stem cell growth. GABA has been found in the intestine, stomach, pancreas, fallopian tubes, uterus, ovaries, testis, kidney, bladder, lung, liver, lungs, melatonin and eye lens.(Source)

GABA makes up 40% of nerve cells, where glutamate makes up 30%. Glutamate offers excitability to the nervous system and also the brain synthesizes glutamate into GABA, which regulates the excitability, causing a check and balance, or ying and yang effect of controlling the functions. GABA inhibits nerve cells from growing, aggressive behavior, and regulates hyperactivity. (Source)

How Marijuana Inhibits GABA

Marijuana use effects the neurotransmitter GABA by blocking it. The result is increasing dopamine levels which normally GABA inhibits or regulates. Dopamine offers a mood shift of reward for the brain that is released with sex, exercise, appetite, learning, sleep, movement and mood.(Source)

Cannabis effects the cannabinoid receptors, namely Cb1 and Cb2 that mimic a naturally created endogenous molecule, anadamide. Anadamide is an Omega 6 fatty acid that regulates appetite, cognition, emotion, memory, mood and pain. Delta-9-tetrahydrocannabinol (THC) and other Cannabinoids found in marijuana can effect anadamide and therefore effect the endocannabinoid central nervous system.

THC, for instance, binds to the CB1 receptors, which reduces the enzyme cAMP which results in less protein kinase A. This results in potassium and calcium channels that ends up reducing the amount of neurotransmitters being released. This chemical reaction is the result of reducing GABA. A reduction in GABA results in an increase in dopamine. Dopamine do not effect the CB1 receptors. (Source)

Treatments From Inhibiting GABA

Research is still needed for more conclusive results, but promising studies and theories show that cannabis can be an effective treatment for it's ability to effect GABA including:

Tinnitus – A brain induced ringing in the ear.
Fibromyalgia – Tenderness in joints, muscles and other soft tissues.
Anxiety – Stress inducing fear, unease and worry.
Addiction – The difficulty to stop using substances.
Schizophrenia – Difficulty knowing what is real and not, thinking clearly to have normal responses.

Source:

Thursday, September 11, 2014

Benefits of Cannabis for Schizophrenia

Schizophrenia is mental disability where the person has inappropriate thoughts, emotions, behavior feelings and actions causing an altered reality of delusions and hallucinations. (Source) Studies have found a theory that the human endogenous cannabinoid system is a major source of the causes of schizophrenia. (Source) The endogenous cannabinoid system is responsible in the brain to trigger signals relating to appetite, the feeling of pain, mood and memory as well as regulating phychoactive effects by cannabis from the most notable CB1, CB2 and Anandamide receptors of the nervous system (Source).

Studies have shown promising benefits of Marijuana to relieve Schizophrenia symptoms. Cannabis should not be a replacement for prescribed drugs for the condition without talking to your physician. The Drug Enforement Agency DEA has categorized cannabis as a schedule 1 drug, research for cannabis is lacking and conclusive evidence for benefits of Schizophrenia is still in progress.(Source

Here are a collection of studies regarding marijuana and Schizophrenia:

Markus Leweke of the University of Cologne in Germany conducted a study with 39 individuals with schizophrenia giving half cannabidiol (CBD) and the other half Amisulpride, an anti psychotic drug used for schizophrenia treatment. Cannabidiol is derived from the cannabis plant and is an antioxidant anti psycho-active part of the marijuana plant. The results showed that the symptoms equally went down for all subjects, with the people using cannabidiol (CBD) having less side effects. (Source)

Dr. Daniele Piomelli, professor of pharmacology at the University of California-Irvine has studied the anandamide receptors of the nervous system in the endogenous cannabinoid system. Dr. Piomellis theorizes with this study that cannabidiol CBD helps with schizophrenia by saying “What CBD seems to be doing is preventing anandamide from being destroyed”.(Source)

Raquel Levin and Fernanda F. Peres in Brazil did a study on mice with schizophrenia in which they gave Cannabidiol CBD to some mice and WIN55212,2 (synthetic cannabinoid agonist) to the other. Both were able to show positive results in improving sensory gating deficits. The results from the team were “Our results reinforce the role of the endocannabinoid system in the sensorimotor gating impairment related to schizophrenia, and point to cannabinoid drugs as potential therapeutic strategies.” (Source)

Future Studies

Currently, GW Pharmaceuticals is doing a study on their own GWP-42003 which is derived from cannabidiol CBD. They are doing the research in hopes of finding treatment with cannabis for schizophrenia. They have finished phase 1 and it shows promising results and they are now doing phase 2 (Source)

For medication to be introduced in the United States with cannabidiol CBD, it first needs to be FDA approved for study. The FDA has approved experimental use for CBD for the treatment of Dravet syndrome. Soon the FDA is set to allow it for clinical trials in showing safety and tolerability for CBD in children.(Source)

Source: